Biocure Technology Inc. · CSE:CURE.X
Biocure Technology — Investor Presentation (August 2021)
18 slides from Biocure Technology's investor presentation, August 2021
Slide 1: Front Runner in CAR-T Cell Therapy for Cancer Patients
CSE: CURE│OTCQB: BICTF│FSE: 1WH FRONT RUNNER IN CAR-T CELL THERAPY FOR CANCER PATIENTS Investor Presentation, August 2021 BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │FSE:1WH) 1 INVESTOR BRIEFING – AUGUST 2021
Slide 2: Biocure Pharma Intro
BIOCURE PHARMA INTRO Using genetic engineering to deliver new treatments for aggressive cancers Biocure Pharma Biocure, is a leading headquartered in biotech company Korea, has joint developing its venture partners in CAR-T cell therapy Asia and Europe for leukemia, lung, with planned clinical breas
Slide 3: History to Date
HISTORY TO DATE Substantial investment and business progression made 2021 Phase I clinical trial planned 2021 Dual listing on Frankfurt Exchange 2018 Completed 2020 2017 pre-clinical trial of MOU with Announced CAR-T CAR-T cell Therapy S&B Biopharma, 2016 cell Therapy BCP401 – Bulgaria for building
Slide 4: Business Highlights
BUSINESS HIGHLIGHTS Positioned to capture value by commercializing BCP401 Front runner to commercialize its BCP401 CAR-T cell therapy in Korea Two terminally ill patients showed Complete Remission after 1 month of BCP401 CAR-T cell therapy High efficacy and safety data for BCP401 in place in readine
Slide 5: CAR-T Cell Therapy
CAR-T CELL THERAPY CSE: CURE│OTCQB: BICTF│FSE: 1WH BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │FSE:1WH) 5 INVESTOR BRIEFING – AUGUST 2021
Slide 6: CAR-T Cell Therapy: Cancer Breakthrough
CAR-T CELL THERAPY: CANCER BREAKTHROUGH Complete remission was achieved in 90% of patients from a single injection Acute lymphoblastic 2012-14 2017-18 leukemia (ALL) is difficult to UPenn: A total of 30 children and U.S. FDA approved, Kymriah®, treat despite the availability adults received CAR-T ce
Slide 7: CAR-T Cell Therapy Mechanism
CAR-T CELL THERAPY MECHANISM Uses a patient’s own immune system to fight certain types of cancer T-cells are T-cells are CAR-T cells CAR-T cells CAR-T cells tracks collected from genetically are multiplied are infused down specific the patient modified with into the body antigen on the Chimeric Anti
Slide 8: Market Situation
MARKET SITUATION Biocure is targeting market entry with a cost-effective solution Therapy Target Manufacturer Stage Indication Pricing (US$) Kymriah® (tisagenlecleucel) CD19 Novartis FDA approved ALL $475,000, per 1 dose Yescarta® (axicabtagene ciloleucel) CD19 Gilead / KITE FDA approved Non-Hodgkin
Slide 9: Biocure Pharm
BIOCURE PHARM CSE: CURE│OTCQB: BICTF│FSE: 1WH BIOCURE TECHNOLOGY INC. (CSE:CURE │OTCQB:BICTF │FSE:1WH) 9 INVESTOR BRIEFING – AUGUST 2021
Slide 10: Biocure Pharm Business Plan
BIOCURE PHARM BUSINESS PLAN Strategic growth plan 2. JV to progress international 1. Progress BCP401 opportunities 3. Uplisting to a for ALL in Korea MOU in Bulgaria for major US exchange Complete Phase I & II manufacturing, Significant technology- clinical trials, obtain progress BCP402 for based I
Slide 11: Our Pipeline
OUR PIPELINE Numerous value inflection points for coming 24 months Program Indication (Target) Approach & Status Discovery Pre-clinical Phase I Phase II Exit • CAR-T therapy targeting CD19 antigen Conditional • Preclinical efficacy / toxicity test completed, together with market establishment of man
Slide 12: BCP401 Value Proposition
BCP401 VALUE PROPOSITION Attractive proposition clinically and operationally Key Features Benefit Established safety profile Pre-clinical data shown to have a good efficacy and toxicity test profile In-built ‘targeting’ of BCP401 for CD19 Delivered via IV infusion with CAR-T cell therapy targeting C
Slide 13: Investigator Clinical Trial of BCP401
INVESTIGATOR CLINICAL TRIAL OF BCP401 Conducted at Beijing University Hospital in China using CAR-T cell therapy Overall Response Rate to BCP401 CAR-T cell therapy for trial provided by Pharos Vaccine, a collaborative research and development company of BiocurePharm 56 subjects with relapse/refracto
Slide 14: Market Potential of BCP401
MARKET POTENTIAL OF BCP401 Substantial revenue potential once in market Number of patients with lymphatic leukemia in Korea Leukemia is the most prevalent disease 6,630 for children under 14 years $1.99B 6,350 Biocure is targeting a one-time $1.91B treatment fee of approx. 340 million won (approx. 3
Slide 15: Board of Directors and Management
BOARD OF DIRECTORS AND MANAGEMENT Experienced leadership team Dr. Sang Mok Lee Dr. Bjorn Cochlovius Mr. Konstantin Mr Collin (Sang Goo) Kim Mr. Berkan Unal Dr. Danny Joh CEO & Founder, President Lichtenwald Director Director Director Director CFO, Director • President and CEO of • Bjoern Cochlovius,
Slide 16: Capital Structure
CAPITAL STRUCTURE Capital structure No. of shares % held Board and management 30.0m 28.1% Other shareholders 76.6m 71.9% Total shares on issue 106.6m 100.0% Options (exercise price CAD0.30) 7.57m Warrants (exercise price CAD0.21) 9.05m Share price CAD0.175 Market capitalisation (undiluted) CAD18.65m
Slide 17: Notices & Disclaimer
NOTICES & DISCLAIMER Important Notice & Disclaimer “Forward Looking Statements” Disclaimer This presentation has been prepared by the management of the ‘Company’ in The documents provided contain statements related to our future business and connection with meetings with private and institutional in
Slide 18: Contact
CSE: CURE│OTCQB: BICTF│FSE: 1WH Website: https://biocuretech.com/ Email : info@biocuretech.com Address: 300-1055 West Hastings Street Vancouver, BC V6E 2E9 Canada Phone +1 604-609-7146 Investor Relations (North America) Purple Crown Communications Corp. Ms Julie Hajduk Email: Julie@purplecrown.ca BI
Biocure Technology — Investor Presentation (August 2021) on 6ix